Palbociclib
Brand: Ibrance (US/EU) / Palbociclib (IN/BD)
Anticancer
CDK4/6 inhibitor
Pharmacokinetics
| Half-life | 29 hours |
| Tmax | 8 h |
| Bioavailability | 46 % (approx) |
| Protein Binding | 85 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | CYP3A4 substrate. Major dose limitation = neutropenia. Monitor CBC monthly. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Neutropenia, infections, stomatitis, fatigue
Contraindications:
Severe neutropenia, active uncontrolled infection
Precautions:
CBC monitoring required; avoid strong CYP3A inhibitors